Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
Chevallier
Patrice
P
Robillard
Nelly
N
Ayari
Sameh
S
Guillaume
Thierry
T
Delaunay
Jacques
J
Mechinaud
Francoise
F
Avet-Loiseau
Herve
H
Mohty
Mohamad
M
Harousseau
Jean-Luc
JL
Garand
Richard
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000097:blood*; D015214:Antigens, Differentiation, Myelomonocytic / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D063268:Sialic Acid Binding Ig-like Lectin 3; D055815:Young Adult
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000970:Antineoplastic Agents; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab